1.Wright, Cl, Fischer, H, Whalen, PJ, McInerney, SC, Shin, LM, Rauch, SL. Differential prefrontal cortex and amygdala habituation to repeatedly presented emotional stimuli. Neuroreport. 2001;12:379–383.
2.Falls, WA, Miserendino, MJ, Davis, M, et al.Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci. 1992;12:854–863.
3.Lu, KT, Walker, DL, Davis, M. Mitogen-activated protein kinase cascade in the basolateral nucleus of amygdala is involved in extinction of fear-potentiated startle. J Neurosci. 2001;21:RC162.
4.Walker, DL, Ressler, KJ, Lu, KT, Davis, M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci. 2002;22:2343–2351.
5.Myers, KM, Davis, M. Behavioral and neural analysis of extinction. Neuron. 2002;36:567–584.
6.Ledgerwood, L, Richardson, R, Cranney, J. Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci. 2003;117:341–349.
7.Richardson, R, Ledgerwood, L, Cranney, J. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications. Learn Mem. 2004;11:510–516.
8.Hofmann, SG, Meuret, AE, Smits, JA, et al.Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63:298–304.
9.Ressler, KJ, Rothbaum, BO, Tannenbaum, L, et al.Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry. 2004;61:1136–1144.
10.First, MB, Spitzer, RL, Gibbon, M, Williams, JB. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). New York, NY: Psychiatric Institute, Biometrics Research; 1995.
11.Beck, AT, Epstein, N, Brown, G, Steer, RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893–897.
12.Beck, AT, Steer, RA. Beck Anxiety Inventory Manual. San Antonio, Tex: The Psychological Corporation, Harcourt Brace and Company; 1990.
13.Beck, AT, Ward, CH, Mendelson, M, Mock, J, Erbaugh, J. An inventory for measuring depression. Arch Gen Psychiatry. 196;4:561–571.
14.Spielberger, CD, Gorsuch, RL, Lushene, RD. STAI: Manual for the State-Trait Anxiety Inventory. Palo Alto, Calif: Consulting Psychologists Press; 1970.
15.Ekman, P, Friesen, WV. Pictures of Facial Affect. Palo Alto, Calif: Consulting Psychologists Press; 1976.
16.Crane, GE. Cyloserine as an antidepressant agent. Am J Psychiatry. 1959;115:1025–1026.
17.van Berckel, BN, Lipsch, C, Timp, S, et al.Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology. 1997;16:317–324.
18.Wedig, MM, Rauch, SL, Albert, MS, Wright, CI. Differential amygdala habituation to neutral faces in young and elderly adults. Neurosci Lett. 2005;385:114–119.
19.Fischer, H, Wright, Cl, Whalen, PJ, McInerney, SC, Shin, LM, Rauch, SL. Brain habituation during repeated exposure to fearful and neutral faces: a functional MRI study. Brain Res Bull. 2003;59:387–392.
20.Holt, DJ, Weiss, AP, Rauch, SL, et al.Sustained activation of the hippocampus in response to fearful faces in schizophrenia. Biol Psychiatry. 2005;57:1011–1019.
21.Wright, Cl, Martis, B, Schwartz, CE. Novelty responses and differential effects of order in the amygdala, substantia innominata, and inferior temporal cortex. Neuroimage. 2003;18:660–669.
22.Cox, RW. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res. 1996;29:162–173.
23.Wright, CI, Williams, D, Feczko, E, et al.Neuroanatomical correlates of extraversion and neuroticism. Cereb Cortex. 2006;16:1809–1819.
24.Fischl, B, van der Kouwe, A, Destrieux, C, et al.Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14:11–22.
25.Rauch, SL, Shin, LM, Wright, CI, et al.Neuroimaging studies of amygdala function in anxiety disorders. Ann N Y Acad Sci. 2003;985:389–410.
26.Shin, LM, Wright, Cl, Cannistraro, PA. A functional magnetic resonance imaging study of amygdala and medial prefrontal cortex responses to overtly presented fearful faces in posttraumatic stress disorder. Arch Gen Psychiatry. 2005;62:273–281.
27.Birbaumer, N, Grodd, W, Diedrich, O. fMRI reveals amygdala activation to human faces in social phobics. Neuroreport. 1998;9:1223–1226.
28.Furmark, T, Tillfors, M, Marteinsdottir, I, et al.Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry. 2002;59:425–433.
29.Regier, DA, Boyd, JH, Burke, JD, et al.One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry. 1988;45:977–986.
30.Drevets, WC, Videen, TO, Price, JL, et al.A functional anatomical study of unipolar depression. J Neurosci. 1992;12:3628–3641.
31.Drevets, WC, Price, JL, Bardgett, ME, Reich, T, Todd, RD, Raichle, ME. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol Biochem Behav. 2002;71:431–447.
32.Yurgelun-Todd, DA, Gruber, SA, Kanayama, G. fMRI during affect discrimination in bipolar affective disorder. Bipolar Disord. 2000;2:237–248.
33.Drevets, WC, Bogers, W, Raichle, ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol. 2002;12:527–544.
34.Sheline, YI, Barch, DM, Donnelly, JM, Ollinger, JM, Snyder, AZ, Mintun, MA. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry. 2001;50:651–658.
35.Abel, KM, Allin, MP, Kucharska-Pietura, K. Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. Neuroreport. 2003;14:387–391.
36.Millan, MJ. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review. Curr Drug Targets CNS Neurol Disord. 2002;1:191–213.
37.Zarate, CA, Singh, JB, Carlson, PJ, et al.A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–864.
38.Parnas, AS, Weber, M, Richardson, R, et al.Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem. 2005;83:224–231.
39.Quartermain, D, Mower, J, Rafferty, MF, Herting, RL, Lanthorn, TH. Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol. 1994;257:7–12.
40.Cammarota, M, Barros, DM, Vianna, MR, et al.The transition from memory retrieval to extinction. An Acad Bras Cienc. 2004;76:573–582.
41.Krystal, JH, Sanacora, G, Blumberg, H, et al.Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry. 2002;7(suppl 1):S71–S80.
42.Inanobe, A, Furukawa, H, Gouaux, E, et al.Mechanism of partial agonist action at the NR1 subunit of NMDA receptors. Neuron. 2005;47:71–84.
43.Fitzgerald, DA, Angstadt, M, Jelsone, LM, Nathan, PJ, Phan, KL. Beyond threat: amygdala reactivity across multiple expressions of facial affect. Neuroimage. 2006;30:1441–1448.
44.Breiter, HC, Etcoff, NL, Whalen, PJ. Response and habituation of the human amygdala during visual processing of facial expression. Neuron. 1996;17:875–887.
45.van Berckel, BN, Lipsch, C, Gispen-de Wied, C. The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology (Berl). 1998;138:190–197.